文拉法辛联合疏肝解郁胶囊治疗脑卒中后抑郁疗效观察

Effect of venlafaxine sustained-release tablet combined with Shuganjieyu capsule in the treatment of post-stroke depression

目的 比较文拉法辛缓释片联合疏肝解郁胶囊与单纯使用盐酸文拉法辛缓释片治疗脑卒中后中重度抑郁的疗效和安全性.方法 选择脑卒中后中重度抑郁的患者70例,按随机数字表法分成两组,每组各35例.对照组单纯使用文拉法辛缓释片治疗,研究组采用文拉法辛缓释片联合疏肝解郁胶囊治疗,观察疗程6周,定期对患者进行汉密顿抑郁量表（HAMD）（17项）及副反应量表（TESS）评估.结果 治疗第6周末时,研究组总有效率为88.57％,对照组总有效率为65.71％,研究组总有效率明显高于对照组（x2=5.19,P＜0.05）；治疗第6周末时两组HAMD评分分别为（16.42 ±6.07）分,（10.54 ±5.23）分,组间评分差异有统计学意义（=4.34,P＜0.01）.两组TESS评分差异无统计学意义（=0.18,P ＞0.05）.结论 盐酸文拉法辛缓释片联合疏肝解郁胶囊治疗脑卒中后中重度抑郁是一种安全有效的方法.

Objective To compare the effect and safety of venlafaxine sustained-release tablet combined with Shuganjieyu capsule and venlafaxine sustained-release tablet used singlely in the treatment of moderate to severe poststroke depression. Methods 70 patients suffered from moderate to severe post-stroke depression were randomly divided into two groups,35 cases in each group. The patients in the control group were only treated with venlafaxine sustained-release tablet, and the patients in the study group were treated by venlafaxine sustained-release tablet combined with Shuganjieyu capsule. The treatment lasted 6 weeks. The therapeutic effect and safety were evaluated by the positive and negative syndrome scale of HAMD （ 17 items）, and treatment emergent symptom scale of TESS. Results After treatment for 6 weeks,the total effective rate of the study group was 88.57% ,which was significantly higher than 65.71% of the control group （X^2 = 5.19, P 〈 0.05 ）. The HAMD score of the study group was （ 16.42 ± 6.07 ） points, and the HAMD score of the control group was（ 10.54 ± 5.23 ）points after 6 weeks. The difference was statistically significant between the two groups （ t = 4.34, P 〈 0.01 ）. The difference of TESS score between two groups wasnot significant（ t = O. 18, P 〉 O. 05 ）. Conclusion Venlafaxine sustained-release tablet combined with Shuganjieyu capsule is effective and safe in the treatment of moderate to severe post-stroke depression.